Clinical TrialsThe SkinJect program in nodular basal cell carcinoma has shown impressive results with a 60% complete response at interim analysis, suggesting significant potential for success.
Market ExpansionMedicus has announced the expansion of the SkinJect program into the United Arab Emirates, marking progress in its international clinical trials.
Product DevelopmentThe Antev acquisition deal will bring on board Teverelix, a next-generation GnRH antagonist that diversifies the Medicus pipeline and adds unlocked value potential.